linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Pharma

Vaccine development takes years. But one for the pandemic by early 2021? Here’s a reality check.

Around 120 Covid-19 vaccines are under research across the world. Besides being a long-drawn process, the lack of convincing data and the fickle nature of the novel coronavirus would call for a tempered expectation of a vaccine. But some scientists have promised that millions of doses will be available by early 2021. So, what’s fuelling such optimism?
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
vikasdandekar1
11 Jun 2020 10 Mins Read 9 comments
A laboratory technician with a dose of a Covid-19 vaccine candidate, ready for trial on monkeys, at the National Primate Research Center of Thailand at Chulalongkorn University, in Saraburi on May 23, 2020. Getty Images
A laboratory technician with a dose of a Covid-19 vaccine candidate, ready for trial on monkeys, at the National Primate Research Center of Thailand at Chulalongkorn University, in Saraburi on May 23, 2020.
The self-effacing bioscience labs on the sprawling campus of the Indian Institute of Technology Guwahati belie the battle being waged inside. A team of scientists helmed by Sachin Kumar, a doctorate in molecular virology from the University of Maryland, the US, is hard at work to develop a vaccine against the wily SARS-CoV-2 virus. In the early days
even in gene therapy. “While the group of scientists may have factored in those limitations, there is not enough out in public domain,” the virologist says. Back at IIT Guwahati, between such rounds of euphoria and hard reality, Kumar hopes his work moves slowly but steadily and makes news when he is done. ( Graphics by Mohammad Arshad)
The self-effacing bioscience labs on the sprawling campus of the Indian Institute of Technology Guwahati belie the battle being waged inside. A team of scientists helmed by Sachin Kumar, a doctorate in molecular virology from the University of Maryland, the US, is hard at work to develop a vaccine against the wily SARS-CoV-2 virus. In the early days even in gene therapy. “While the group of scientists may have factored in those limitations, there is not enough out in public domain,” the virologist says. Back at IIT Guwahati, between such rounds of euphoria and hard reality, Kumar hopes his work moves slowly but steadily and makes news when he is done. ( Graphics by Mohammad Arshad)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

CONTRIBUTORS WHO HAVE COMMENTED ON THIS STORY

test

user Vikas Dandekar ET Prime, Editor - Pharma and Life Sciences

test

user ANUMOY KAR

test

user Sudip Kumar Lahiri NTPC, Retd Addl GM Finance

Current Edition

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]